Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

Cancer Research

Volumn 65, Issue 18, 2005, Pages 8059-8064

  Emens, Leisha A ^a   Jaffee, Elizabeth M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAS LIGAND; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELPHALAN; MITOMYCIN C; PACLITAXEL; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR VACCINE; VACCINE; VASCULOTROPIN;

ADVANCED CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER PREVENTION; CANCER RELAPSE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; COMBINED MODALITY THERAPY; DRUG SYNERGISM; HUMANS; IMMUNE TOLERANCE; NEOPLASMS;

EID: 24944478531     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1797     Document Type: Review

References (52)

1. Old L, Boyse E, Clarke D. Antigenic properties of chemically induced tumors. Ann NY Acad Sci 1962;101:80-106.
2. Dunn G, Old L, Schreiber R. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
3. Ochsenbein A, Klenerman P, Karrer U, et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 1999;96:2233-8.
4. Perez-Diaz A, Spiess P, Restifo N, Matzinger P, Marincola F. Intensity of the vaccine-elicited immune response determines tumor clearance. J Immunol 2002;168:338-47.
5. Walker L, Abbas A. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol 2001;21:11-9.
6. + T cell tolerance and cancer immunotherapy. J Immunother 2003;26:1-11.
7. + T cells to the antitumor immune response. J Exp Med 2005;210:1-13.
8. McHugh R, Shevach E. The role of suppressor T cells in regulation of immune responses. J All Clin Immunol 2002;110:693-702.
9. Pardoll D. Spinning molecular immunology into successful immunotherapy. Nat Rev 2002;2:227-38.
10. Khoury S, Sayegh M. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 2004;20:529-38.
11. Marincola F, Jaffee E, Hicklin D, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
12. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999;5:611-5.
13. Knutson KL, Almand B, Dang Y, Disis ML. Neu antigen-variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res 2004;64:1146-51.
14. Kageshita R, Hira S Ono T, Hickli D, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999;154:745-54.
15. von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7:1181-91.
16. Jaffee E, Hruban R, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-56.
17. + T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200:297-306.
18. Keane M, Ettenberg S, Nau M, Russell E, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999;59:734-41.
19. Zisman A, Ng C-P, Pantuck A, Bonavida B, Belldegrun A. Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2/TRAIL-mediated apoptosis. J Immunother 2001;24:459-71.
20. Tong Y, Song W, Crystal R. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 2001;61:7530-5.
21. Yu B, Kusmartsev S, Cheng F, et al. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental cancer. Clin Cancer Res 2003;9:285-94.
22. Demaria S, Volm M, Shapiro R, et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001;7:3025-303.
23. Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M. Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J Biol Chem 2000;275:2251-4.
24. Bryd-Leifer C, Block E, Takeda K, Akira S, DIng A. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 2001;31:2448-57.
25. Machiels J-P, Reilly R, Emens L, et al. Cyclophosphamide, Doxorubicin, and Paclitaxel enhance the anti-tumor immune response of GM-CSF secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001;61:3689-97.
26. Wang J, Kobayashi M, Han M, et al. MyD88 is involved in the signaling pathway for Taxol-induced apoptosis and TNF-α expression in human myelomonocytic cells. Br J Hematol 2002;118:638-45.
27. Coral S, Sigalotti L, Altomonte M, et al. 5-Aza-2′-deoxycytidine- induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 2002;8:2690-5.
28. Correale P, Aquino A, Giuliani A, et al. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A*02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer 2003;104:437-45.
29. Yang S, Haluska F. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin-granzyme-and Fas-mediated pathways. J Immunol 2004;172:4599-608.
30. Bocci G, Nicolaou K, Kerbel R. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic agents. Cancer Res 2002;62:6938-43.
31. Emens LA, Machiels JPH, Reilly RT, Jaffee EM. Chemotherapy: friend or foe to cancer vaccines? Curr Opin Mol Ther 2001;3:77-82.
32. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44.
33. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8.
34. Gorelik L, Prokhorova A, Mokyr M. Low-dose Melphalan induced shift in the production of Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother 1994;39:117-25.
35. high T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000;95:2024-30.
36. Nigam A, Yacavone R, Zahurak M, et al. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Cancer 1998;12:161-70.
37. Nowak A, Robinson B, Lake R. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 2002;62:2353-8.
38. Guy C, Webster M, Schaller M, Parsons T, Cardiff R, Muller W. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578-82.
39. Reilly RT, Gottlieb MBC, Ercolini AM, et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000;60:3569-76.
40. Ercolini A, Machiels J-P, Chen Y, et al. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu transgenic mice. J Immunol 2003;170:4273-80.
41. Eralp Y, Wang X, Wang J, Maughan M, Polo J, Lachman L. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER-2/neu in a murine mammary carcinoma model. Breast Cancer Res 2004;6:R275-83.
42. Laheru D, Nemunaitis J, Biedrzycki B, et al. A feasibility study of a GM-CSF-secreting irradiated whole cell allogeneic vaccine (GVAX) alone or in sequence with Cytoxan for patients with locally advanced or metastatic pancreatic cancer. Proceedings of the AACR: Pancreatic Cancer 2004: Advances and Challenges: abstract 54.
43. Cho B, Rao V, Ge Q, Eisen H, Chen J. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med 2000;192:549-56.
44. Mackall C, Bare C, Granger L, Sharrow S, Titus J, Gress R. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 1996;156:4609-16.
45. Hu HM, Poehlein C, Urba W, Fox B. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 2002;62:3914-9.
46. Borrello I, Sotomayor E, Rattis F-M, Cooke S, Gu L, Levitsky H. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 2000;95:3011-9.
47. Teshima T, Mach N, Hill G, et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res 2001;61:162-71.
48. Luznik L, Slansky JE, Jalla S, et al. Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood 2003;101:1645-52.
49. Dudley M, Wunderlich J, Robbins P, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
50. Dudley M, Wunderlich J, Yang J, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
51. + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005;105:245-50.
52. Robbins P, Dudley M, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004;173:7125-30.